A Fluorescent Styrylquinoline with Combined Therapeutic and Diagnostic Activities against Alzheimer’s and Prion Diseases
Matteo Staderini(Universidad Complutense de Madrid), María Laura Bolognesi(University of Bologna), Giuseppe Legname(International Center for Advanced Studies), Suzana Aulić(Scuola Internazionale Superiore di Studi Avanzati), M. Antonia Martín(Virginia Commonwealth University), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), J. Carlos Menéndez(Universidad Complutense de Madrid), Hoang Ngoc Tran(Université de Bordeaux), Vincenza Andrisano(University of Bologna), Víctor González‐Ruiz(Universidad San Pablo CEU), Nieves Cabezas(Universidad Complutense de Madrid), Manuela Bartolini(University of Bologna), Daniel I. Pérez(Cedars-Sinai Medical Center)
Cited by 58
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334
TNFα disrupts blood brain barrier integrity to maintain prolonged depressive-like behavior in mice
|Brain Behavior and Immunity|2018|293